HC Wainwright & Co. Reiterates Buy on Harmony Biosciences Hldgs, Maintains $55 Price Target
Harmony Biosciences (HRMY) Stock May Be Undervalued On Earnings Power
HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth
Harmony Biosciences Holdings, Inc. Q3 2026 Earnings Call Summary
Harmony Biosciences (HRMY) Q3 2026 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript
Harmony Biosciences Q3 Earnings Call Highlights
Harmony Biosciences Holdings (NASDAQ:HRMY) Q3 2026 Earnings Miss Overshadows WAKIX Growth
Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile
Harmony Biosciences Hldgs Q3 2026 Earnings Call Transcript
Harmony Biosciences Reports Q3 WAKIX Sales Of $269M, Driven By Strong Demand With 400 Net Patient Adds; Appoints Peter Anastasiou As CEO, Effective January 1, 2027
Harmony Biosciences Q3 EPS $0.81 Misses $1.10 Estimate, Sales $268.917M Miss $273.078M Estimate
Harmony Biosciences Hldgs Affirms FY2026 Sales Guidance of $1.000B-$1.040B vs $1.028B Est
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth
Harmony Biosciences Grapples With A Leadership Transition That Spooked Investors
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?
Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over It
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026
Needham Reiterates Buy on Harmony Biosciences Hldgs, Maintains $50 Price Target
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.